GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » Asset Turnover

Actinium Pharmaceuticals (Actinium Pharmaceuticals) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Actinium Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.08 Mil. Actinium Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $85.19 Mil. Therefore, Actinium Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Actinium Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was -93.28%. It is also linked to ROA % through Du Pont Formula. Actinium Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -43.78%.


Actinium Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Actinium Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals Asset Turnover Chart

Actinium Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.02 0.01 -

Actinium Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actinium Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, Actinium Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinium Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Asset Turnover falls into.



Actinium Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Actinium Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.081/( (114.192+81.445)/ 2 )
=0.081/97.8185
=0.00

Actinium Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0.081/( (88.944+81.445)/ 2 )
=0.081/85.1945
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Actinium Pharmaceuticals  (AMEX:ATNM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Actinium Pharmaceuticals's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-37.296/39.981
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-37.296 / 0.324)*(0.324 / 85.1945)*(85.1945/ 39.981)
=Net Margin %*Asset Turnover*Equity Multiplier
=-11511.11 %*0.0038*2.1309
=ROA %*Equity Multiplier
=-43.78 %*2.1309
=-93.28 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Actinium Pharmaceuticals's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-37.296/85.1945
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-37.296 / 0.324)*(0.324 / 85.1945)
=Net Margin %*Asset Turnover
=-11511.11 %*0.0038
=-43.78 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Actinium Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinium Pharmaceuticals (Actinium Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
275 Madison Avenue, 7th Floor, New York, NY, USA, 10016
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Executives
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin officer: VP, Finance and Corporate Dev. 955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig officer: Chief Scientific Officer 21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell director 521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty director 643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur officer: Chief Commercial Officer 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray officer: Executive Vice President 14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center 10 percent owner 1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa director 138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave director, officer: President and CEO 4 WATER STREET, EDISON NJ 08820
Richard I Steinhart director 125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc 10 percent owner C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd. 10 percent owner C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000

Actinium Pharmaceuticals (Actinium Pharmaceuticals) Headlines

From GuruFocus